A5069593908- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- CNS Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Healthcare professionals’ stress and burnout
- Innovations in Medical Education
- Acute Myeloid Leukemia Research
- Multiple and Secondary Primary Cancers
- Social Media in Health Education
- Childhood Cancer Survivors' Quality of Life
- Economic and Financial Impacts of Cancer
- COVID-19 and healthcare impacts
- Cutaneous lymphoproliferative disorders research
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Treatments and Mutations
- Platelet Disorders and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cancer Genomics and Diagnostics
- Intramuscular injections and effects
- Cancer survivorship and care
University of Colorado Denver
2017-2025
University of Colorado Cancer Center
2022-2025
University of Chicago
2020-2024
University of Colorado Anschutz Medical Campus
2023
University of Chicago Medical Center
2022-2023
Christ University
2018
Baylor College of Medicine
2017
Albany Medical Center Hospital
2014
Hungarian National Blood Transfusion Service
2013
Union College
2012
Abstract Multiple myeloma (MM) is a cancer of older adults and those who are more frail at high risk poor outcomes. Current tools for identifying categorizing patients often static measured only the time diagnosis. The concept dynamic frailty (i.e. changing over time) largely unexplored in MM. In our study, with newly-diagnosed MM received novel drugs between years 2007–2014 were identified Surveillance, Epidemiology, End Results (SEER)-Medicare linked databases. Using previously published...
Checkpoint inhibitor (CPI) therapy with anti-PD-1 antibodies has been associated mixed outcomes in small cohorts of patients relapsed aggressive B-cell lymphomas after CAR-T failure. To define CPI efficacy more definitively this population, we retrospectively evaluated clinical a large cohort 96 receiving failure across 15 US academic centers. Most (53%) had diffuse lymphoma, were treated axicabtagene ciloleucel (53%), early (≤180 days) (83%), and received pembrolizumab (49%) or nivolumab...
The traditional model of promotion and tenure in the health professions relies heavily on formal scholarship through teaching, research, service. Institutions consider how much weight to give activities each these areas determine a threshold for advancement. With emergence social media, scholars can engage wider audiences creative ways have broader impact. Conventional metrics like h-index do not account media Social engagement is poorly represented most curricula vitae (CV) therefore...
Rare cases of COVID-19 vaccinated individuals develop anti-platelet factor 4 (PF4) antibodies that cause thrombocytopenia and thrombotic complications, a syndrome referred to as vaccine-induced immune (VITT). Currently, information on the characteristics persistence anti-PF4 VITT after Ad26.COV2.S vaccination is limited, available diagnostic assays fail differentiate ChAdOx1 nCoV-19-associated from similar clinical disorders, namely heparin-induced (HIT) spontaneous HIT. Here we demonstrate...
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors immunoarchitectural patterns (IAPs) for all stages pediatric adult patients with NLPHL.
Treatment of newly diagnosed multiple myeloma (NDMM) with a quadruplet regimen consisting monoclonal antibody, proteasome inhibitor, immunomodulatory imide, and corticosteroid has been associated improved progression-free survival (PFS) compared triplet regimens. The optimal combination, whether this obviates the need for frontline autologous stem cell transplant (ASCT), remains unknown. We evaluated elotuzumab weekly carfilzomib, lenalidomide, dexamethasone (Elo-KRd) without ASCT in NDMM.To...
There is a paucity of large-scale data delineating outcomes and prognostication older patients with primary central nervous system lymphoma (PCNSL). We retrospectively analyzed 539 newly-diagnosed PCNSL ages ≥60 years across 20 U.S. academic centers. The median age was 70 (range 60-88); at least one geriatric syndrome present in 46%; the Cumulative Index Ratings Scale-Geriatrics (CIRS-G) score 6 (range, 0-27); 36% had impairment activities daily living (ADL). most common induction regimens...
Anti-PD-1 based therapies and brentuximab vedotin (BV) have significantly improved survival in patients with classic Hodgkin lymphoma (cHL) been incorporated into earlier lines of therapy. However, there is insufficient data regarding the clinical outcomes who develop refractory disease or become intolerant BV anti-PD-1 (double refractory/intolerant; DR/INT). Here, we evaluated DR/INT cHL from 15 US academic medical centers. A total 173 were identified as DR/INT. The median overall time...
Venetoclax showed promising activity in a small phase II trial relapsed/refractory Waldenström macroglobulinemia (WM). To report the clinical of venetoclax and prognostic factors associated with outcomes larger cohort, we retrospectively identified 76 patients lymphoplasmacytic lymphoma (LPL)/WM treated monotherapy at nine US medical centers. The median age treatment initiation was 66 years. MYD88, CXCR4, TP53 mutations were detected 65 (94%), 23 (40%), 10 (22%) patients, respectively....
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and a promising therapeutic target. mTOR inhibitor temsirolimus (TEM) the immunomodulatory agent lenalidomide (LEN) have overlapping effects within PAM with synergistic potential. This multicenter phase I/II study evaluated combination therapy TEM/LEN patients relapsed refractory lymphomas. Primary endpoints of II were rates complete (CR) overall response (ORR). There 18 I dose-finding study, TEM 25 mg...
We evaluated the efficacy and safety of 24 cycles Dara in combination with carfilzomib (K), lenalidomide (R), dexamethasone (d) without autologous stem cell transplant (ASCT) newly diagnosed multiple myeloma (NDMM) irrespective ASCT eligibility a single-arm, phase II study. The primary endpoint was rate stringent complete response (sCR) and/or measurable residual disease (MRD) < 10-5 by next-generation sequencing (NGS) at end cycle 8 (C8). MRD also assessed on peripheral blood samples using...
MRD2STOP is a pragmatic trial evaluating maintenance therapy cessation guided by measurable residual disease (MRD) negativity in multiple myeloma (MM). Eligible patients had previous MRD < 10
Abstract We performed a phase I study of weekly selinexor, carfilzomib, and dexamethasone (wSKd) in patients with relapsed/refractory multiple myeloma (MM). The primary objective was to identify the maximum tolerated dose (MTD) wSKd. Secondary endpoints included overall response rate (ORR), progression‐free survival (PFS), (OS). Prior exposure/refractoriness carfilzomib permitted. Thirty were enrolled; 26 (87%) had triple‐class exposed disease 6 (20%) received chimeric antigen receptor (CAR)...
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a newly described hematologic disorder, which presents as acute and thrombosis after administration of the ChAdOx1 nCov-19 (AstraZeneca) Ad26.COV2.S (Johnson & Johnson) adenovirus-based vaccines against COVID-19. Due to positive assays for antibodies platelet factor 4 (PF4), VITT managed similarly autoimmune heparin-induced (HIT) with intravenous immunoglobulin (IVIG) non-heparin anticoagulation. We describe case in 50-year-old man...